Linking laboratory and pharmacy: Opportunities for reducing errors and improving care

Archives of Internal Medicine

Volumn 163, Issue 8, 2003, Pages 893-900

  Schiff, Gordon D ^a,b   Klass, David ^c,f   Peterson, Josh ^d   Shah, Gaurav ^a   Bates, David W ^e  

^a Jr Hospital of Cook County   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f VigiLanz Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; CARBAMAZEPINE; CERIVASTATIN; CHLORAMPHENICOL; CLOZAPINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; GENTAMICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISONIAZID; LEVOTHYROXINE SODIUM; METFORMIN; NEUROLEPTIC AGENT; PENICILLIN DERIVATIVE; POTASSIUM CHLORIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; THYROID HORMONE; TROGLITAZONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VANCOMYCIN; WARFARIN;

COMPUTER SYSTEM; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG INTOXICATION; DRUG MONITORING; FOLLOW UP; HEALTH CARE QUALITY; HOSPITAL INFORMATION SYSTEM; HUMAN; HYPERKALEMIA; IATROGENIC DISEASE; LABORATORY; LABORATORY TEST; PATIENT CARE; PATIENT MONITORING; PHARMACY; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TITRIMETRY; DRUG INTERACTION; MEDICAL ERROR; MEDICAL INFORMATION SYSTEM; MEDICAL RECORD; MEDICATION ERROR; ORGANIZATION AND MANAGEMENT; SYSTEM ANALYSIS;

CLINICAL LABORATORY INFORMATION SYSTEMS; CLINICAL PHARMACY INFORMATION SYSTEMS; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; MEDICAL ERRORS; MEDICAL RECORD LINKAGE; MEDICATION ERRORS; PATIENT CARE; PRESCRIPTIONS, DRUG; QUALITY OF HEALTH CARE; SYSTEMS INTEGRATION;

EID: 0242500362     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.163.8.893     Document Type: Review

References (106)

1. Schiff GD, Aggarwal HC, Kumar S, McNutt RA. Prescribing potassium despite hyperkalemia: medication errors uncovered by linking laboratory and pharmacy information systems. Am J Med. 2000;109:494-497.
2. Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. JAMA. 2001;286:2839-2844.
3. Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO. Inpatient theophylline toxicity: preventable factors. Ann Intern Med. 1991;114:748-753.
4. Falconnier AD, Haefeli WE, Schoenenberger RA, Surber C, Martin-Facklam M. Drug dosage in patients with renal failure optimized by immediate concurrent feedback. J Gen Intern Med. 2001; 16:369-375.
5. Arbo MD, Snydman DR. Influence of blood culture results on antibiotic choice in the treatment of bacteremia. Arch Intern Med. 1994;154: 2641-2645.
6. Evans RS, Pestotnik SL, Classen DC, Burke JP. Evaluation of a computer-assisted antibioticdose monitor. Ann Pharmacother. 1999;33:1026-1031.
7. Graham DJ, Drinkard CR, Shatin D, Tsong Y, Burgess MJ. Liver enzyme monitoring in patients treated with troglitazone. JAMA. 2001;286:831-833.
8. Bates DW, Cullen D, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. JAMA. 1995; 274:29-34.
9. Hulse RK, Clark SJ, Jackson JC, Warner HR, Gardner RM. Computerized medication monitoring system. Am J Hosp Pharm. 1976;33:1061-1064.
10. Lesar TS, Briceland L, Stein DS. Factors related to errors in medication prescribing. JAMA. 1997; 277:312-317.
11. Gurwitz JH, Field TS, Avorn J, Bates DW. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000;109:87-94.
12. Gandhi TK, Burstin HR, Cook EF, et al. Drug complications in outpatients. J Gen Intern Med. 2000; 15:149-154.
13. Tegeder I, Levy M, Muth-Selbach U, et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br J Clin Pharmacol. 1999;47:557-564.
14. Schiff GD, Rucker TD. Computerized prescribing: building the electronic infrastructure for better medication usage. JAMA. 1998;279:1024-1029.
15. President's Advisory Committee on Consumer Protection and Quality in Healthcare. Building the capacity to improve quality: investing in information systems. In: Quality First: Better Health Care for All Americans. Silver Spring, Md: Agency for Healthcare Research and Quality Publications Clearinghouse; 1998:chap 14.
16. Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA. 1998;280:1311-1316.
17. Balas EA, Austin SM, Mitchell JA, Ewigman BG, Bopp KD, Brown GD. The clinical value of computerized information services: a review of 98 randomized clinical trials. Arch Fam Med. 1996;5: 271-278.
18. Berwick DM, Nolan TW. Overview: cooperating for improvement. Jt Comm J Qual Improv. 1995; 21:573-577.
19. McDonald CJ, Overhage JM, Dexter P, Takesue BY, Dwyer DM. A framework for capturing clinical data sets from computerized sources. Ann Intern Med. 1997;127:675-682.
20. Maibach H, Keenlyside R, Fitzmaurice D, Brogan D, Essien J. Future directions for research in laboratory medicine: the findings of a Delphi survey of stakeholders. Clin Leadersh Manage Rev. 1998;12:221-230.
21. Becich MJ. Information management: moving from test results to clinical information. Clin Leadersh Manag Rev. 2000;14:296-300.
22. Miller WG. The changing role of the medical technologist from technologist to information specialist. Clin Leadersh Manag Rev. 2000;14:285-288.
23. Forsman R. The electronic medical record: implications for the laboratory. Clin Leadersh Manag Rev. 2000;14:292-295.
24. Cohen MR. Medication Errors. Washington, DC: American Pharmaceutical Association; 1999.
25. Evans RS, Pestotnik SL, Classen DC, Bass SB, Burke JP. Prevention of adverse drug events through computerized surveillance. Proc Annu Symp Comput Appl Med Care. 1992:437-441.
26. Bates DW, Teich JM, Lee J, et al. The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc. 1999;6:313-321.
27. Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press; 2001.
28. Gilmet GP, Mallon RP, Griffin BT, Lewandowski JJ. The use of an integrated clinical laboratory and pharmacy diabetes database to provide physician performance feedback in an IPA-model HMO. J Ambulatory Care Manage. 1998;21:12-23.
29. Edelman D. Outpatient diagnostic errors: unrecognized hyperglycemia. Eff Clin Pract. 2002;5: 11-16.
30. Glabman M. Hold the phone! going online with prescription. ACP-ASIM Observer. October 1996. Available at: http://www.acponline.org/journals/news/oct96/presconl.htm. Accessed January 25, 2003.
31. Spicer J. Making patient care easier under multiple managed care plans. Fam Pract Manage. 1998;5(2):38-53.
32. Helfand M, Redfern CC, for the American College of Physicians. Clinical guideline, part 2. Screening for thyroid disease: an update. Ann Intern Med. 1998; 129:144-158.
33. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-412.
34. Marik PE, Fromm L. A case series of hospitalized patients with elevated digoxin levels. Am J Med. 1998;105:110-115.
35. Aronoff GR, Bennett WM. eds. Drug Prescribing in Renal Failure: Dosing Guidelines for adults. 4th ed. Philadelphia, Pa: ACP-ASIM; 1999.
36. Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet. 1999;37:399-431.
37. Centers for Disease Control and Prevention. Drug-induced liver injury: a national and global problem. Westfields Conference Center, Chantilly, Va, February 12-13, 2001. Available at: http://www.fda.gov/cder/livertox/default.htm. Accessed January 25, 2003.
38. Bates DW, Boyle DL, Rittenberg E, et al. What proportion of common diagnostic tests appear redundant? Am J Med. 1998;104:361-368.
39. Schoenenberger RA, Tanasijevic MJ, Jha A, Bates DW. Appropriateness of antiepileptic drug level monitoring. JAMA. 1995;274:1622-1626.
40. Blumenthal D. Total quality management and physicians' clinical decisions. JAMA. 1993;269: 2775-2778.
41. Benneyan JC. Use and interpretation of statistical quality control charts. Int J Qual Health Care. 1998;10:69-73.
42. Kahn MG, Bailey TC, Steib SA, Fraser VJ, Dunagan WC. Statistical process control methods for expert system performance monitoring. J Am Med Inform Assoc. 1996;3:258-269.
43. Berwick DM. Controlling variation in health care: a consultation from Walter Shewhart. Med Care. 1991;29:1212-1225.
44. Staker LV. Changing clinical practice by improving systems: the pursuit of clinical excellence through practice-based measurement for learning and improvement. Qual Manage Health Care. 2000;9:1-13.
45. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342:1266-1271.
46. Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf. 2001;24:483-490.
47. Sundar S, Burma DP, Vaish SK. Digoxin toxicity and electrolytes: a correlative study. Acta Cardiol. 1983;38:115-123.
48. Hall RJ, Gelbart A, Billingham M, Snidow G, Goldman RH. Effect of chronic potassium depletion on digitalis-induced inotropy and arrhythmias. Cardiovasc Res. 1981;15:98-107.
49. Steiner JF, Robbins LJ, Hammermeister KE, Roth SC, Hammond WS. Incidence of digoxin toxicity in outpatients. West J Med. 1994;161:474-478.
50. Skendzel LP, Barnett RN, Platt R. Medically useful criteria for analytic performance of laboratory tests. Am J Clin Pathol. 1985;83:200-205.
51. Gale EA. Lessons from the glitazones: a story of drug development. Lancet. 2001;357:1870-1875.
52. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med. 2001;161:53-58.
53. Schumacher GE, Barr JT. Total testing process applied to therapeutic drug monitoring: impact on patients' outcomes and economics. Clin Chem. 1998;44:370-374.
54. Friedman RB, Young DS, Beatty ES. Automated monitoring of drug-test interactions. Clin Pharmacol Ther. 1978;24:16-21.
55. Young DS. Effects of Preanalytical Variables on Clinical Lab Tests. 2nd ed. Washington, DC: American Assocation for Clinical Chemistry Press; 1997.
56. Gronroos PE, Irjala KM, Huupponen RK, Scheinin H, Forsstrom J, Forsstrom JJ. A medication database: a tool for detecting drug interactions in hospital. Eur J Clin PharmacoL 1997;53:13-17.
57. Forsstrom JJ, Gronroos P, Irjala K, Heiskanen J, Torniainen K. Linking patient medication data with laboratory information system. Int J Biomed Comput. 1996;42:111-116.
58. Kailajarvi M, Takala T, Gronroos P, et al. Reminders of drug effects on laboratory test results. Clin Chem. 2000;46:1395-1400.
59. Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem. 2001;38(pt 4):376-385.
60. Gronroos PE, Irjala KM, Selen GP, Forsstrom JJ. Computerized monitoring of potentially interfering medication in thyroid function diagnostics. Int J Clin Monit Comput. 1997;14:255-259.
61. Gronroos P, Irjala K, Heiskanen J, Torniainen K, Forsstrom JJ. Using computerized individual medication data to detect drug effects on clinical laboratory tests. Scand J Clin Lab Invest Suppl. 1995;222:31-36.
62. Narayanan S. The preanalytic phase: an important component of laboratory medicine. Am J Clin Pathol. 2000;113:429-452.
63. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000; 160:2093-2099.
64. Bagheri H, Michel F, Lapeyre-Mestre M, et al. Detection and incidence of drug-induced liver injuries in hospital: a prospective analysis from laboratory signals. Br J Clin Pharmacol. 2000; 50:479-484.
65. Classen DC, Burke JP, Pestotnik SL, Evans RS, Stevens LE. Surveillance for quality assessment, IV: surveillance using a hospital information system. Infect Control Hosp Epidemiol. 1991;12:239-244.
66. Tierney WM, McDonald CJ. Practice databases and their uses in clinical research. Stat Med. 1991; 10:541-557.
67. Brossette SE, Sprague AP, Jones WT, Moser SA. A data mining system for infection control surveillance. Methods Inf Med. 2000;39:303-310.
68. Brossette SE, Sprague AP, Hardin JM, Waites KB, Jones WT, Moser SA. Association rules and data mining in hospital infection control and public health surveillance. J Am Med Inform Assoc. 1998;5:373-381.
69. Lowrance WW. The promise of human genetic databases. BMJ. 2001;322:1009-1010.
70. Jha AK, Kuperman GJ, Rittenberg E, Teich JM, Bates DW. Identifying hospital admissions due to adverse drug events using a computerbased monitor. Pharmacoepidemiol Drug Saf. 2001;10:113-119.
71. Luchins DJ, Klass D, Hanrahan P, et al. Computerized monitoring of valproate and physician responsiveness to laboratory studies as a quality indicator. Psychiatr Serv. 2000;51:1179-1181.
72. van Wijk MA, van der Lei J, Mosseveld M, Bohnen AM, van Bemmel JH. Assessment of decision support for blood test ordering in primary care: a randomized trial. Ann Intern Med. 2001;134: 274-281.
73. Wetzler HP, Snyder JW. Linking pharmacy and laboratory data to assess the appropriateness of care in patients with diabetes. Diabetes Care. 2000;23:1637-1641.
74. Zhang Q, Safford M, Ottenweller J, et al. Performance status of health care facilities changes with risk adjustment of HbA1c. Diabetes Care. 2000; 23:919-927.
75. Centers for Disease Control Diabetes in Managed Care Work Group. Diabetes mellitus in managed care: complications and resource utilization. Am J Manage Care. 2001;7:501-508.
76. Pogach LM, Hawley G, Weinstock R, et al. Diabetes prevalence and hospital and pharmacy use in the Veterans Health Administration (1994): use of an ambulatory care pharmacy-derived database. Diabetes Care. 1998;21:368-373.
77. Abel SR, Guba EA. Evaluation of an imipenem/cilastatin target drug program. DICP. 1991;25: 348-350.
78. Harrison JH Jr, Rainey PM. Identification of patients for pharmacologic review by computer analysis of clinical laboratory drug concentration data. Am J Clin Pathol. 1995;103:710-717.
79. Schentag JJ, Ballow CH, Fritz AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis. 1993;16:255-264.
80. Hunt DL, Haynes RB, Hanna SE, Smith K. Effects of computer-based clinical decision support systems on physician performance and patient outcomes: a systematic review. JAMA. 1998; 280:1339-1346.
81. Teich JM, Merchia PR, Schmiz JL, Kuperman GJ, Spurr CD, Bates DW. Effects of computerized physician order entry on prescribing practices. Arch Intern Med. 2000;160:2741-2747.
82. Johnston ME, Langton KB, Haynes RB, Mathieu A. Effects of computer-based clinical decision support systems on clinician performance and patient outcome: a critical appraisal of research. Ann Intern Med. 1994;120:135-142.
83. Poller L, Shiach CR, MacCallum PK, et al. Multicentre randomised study of computerised anticoagulant dosage: European Concerted Action on Anticoagulation. Lancet 1998;352:1505-1509.
84. Canas F, Tanasijevic MJ, Ma'Luf N, Bates DW. Evaluating the appropriateness of digoxin level monitoring. Arch Intern Med. 1999;159:363-368.
85. Bates DW, Kuperman GJ, Rittenberg E, et al. A randomized trial of a computer-based intervention to reduce utilization of redundant laboratory tests. Am J Med. 1999;106:144-150.
86. Rind DM, Safran C, Phillips RS, et al. Effect of computer-based alerts on the treatment and outcomes of hospitalized patients. Arch Intern Med. 1994;154:1511-1517.
87. Raschke RA, Gollihare B, Wunderlich TA, et al. A computer alert system to prevent injury from adverse drug events: development and evaluation in a community teaching hospital. JAMA. 1998;280:1317-1320.
88. Shabot MM, LoBue M, Chen J. Wireless clinical alerts for physiologic, laboratory and medication data. Proc AMIA Symp. 2000:789-793.
89. Overhage JM, Tierney WM, Zhou XH, McDonald CJ. A randomized trial of "corollary orders" to prevent errors of omission. J Am Med Inform Assoc. 1997;4:364-375.
90. Bates DW, Cohen M, Leape LL, Overhage JM, Shabot MM, Sheridan T. Reducing the frequency of errors in medicine using information technology. J Am Med Inform Assoc. 2001;8: 299-308.
91. Kuperman GJ, Boyle D, Jha A, et al. How promptly are inpatients treated for critical laboratory results? J Am Med Inform Assoc. 1998;5:112-119.
92. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA. 1991;266:2847-2851.
93. Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc. 1998;5:305-314.
94. Dormann H, Muth-Selbach U, Krebs S, et al. Incidence and costs of adverse drug reactions during hospitalisation: computerised monitoring versus stimulated spontaneous reporting. Drug Saf. 2000;22:161-168.
95. Honigman B, Lee J, Rothchild J, et al. Using computerized data to identify adverse drug events in outpatients. J Am Med Inform Assoc. 2001;8: 254-266.
96. Tate KE, Gardner RM. Computers, quality, and the clinical laboratory: a look at critical value reporting. Proc Annu Symp Comput Appl Med Care. 1993:193-197.
97. Physicians' Desk Reference. 54th ed. Montvale, NJ: Medical Economics Press; 2000.
98. Fulda TR. Computer-based drug-utilization review. N Engl J Med. 1995;333:1290-1291.
99. Peterson JF, Bates DW. Preventable medication errors: identifying and eliminating serious drug interactions [abstract]. J Am Pharm Assoc. 2001;41:159-160.
100. Cavuto NJ, Woosley RL, Sale M. Pharmacies and prevention of potentially fatal drug interactions. JAMA. 1996;275:1086-1087.
101. Schiff GD, Bates DW. Electronic point-of-care prescribing: writing the script. Dis Manage Health Outcomes. 2000;7:297-304.
102. Schiff GD, Rucker TD. Beyond structure-processoutcome: Donabedian's seven pillars and eleven buttresses of quality. Jt Comm J Qual Improv. 2001;27:169-174.
103. Marietti C. Report from HIMSS 2001: medical errors. Healthcare Informatics. April 2001;20-22.
104. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405:857-865.
105. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999; 353:717-719.
106. Edeki TI, Brase DA. Phenytoin disposition and toxicity: role of pharmacogenetic and interethnic factors. Drug Metab Rev. 1995;27:449-469.